Chinese disease control expert: the clinical severity of COVID-19 infection has not changed significantly

At the press conference held by the National Health Commission on May 20, An Zhijie, a researcher from the China Center for Disease Control and Prevention, said that the recent COVID-19 epidemic in some countries and regions has shown a slight upward trend, but the clinical severity of the disease has not changed significantly. To prevent respiratory infectious diseases, it is important to maintain good personal hygiene habits in daily life, wash hands frequently, and ensure adequate ventilation; It is recommended that people with weaker immunity, such as young children, the elderly, and chronic disease patients, receive relevant vaccines to prevent respiratory infectious diseases.

Medical device approval

Changshan Medicine Nadroparin Calcium Injection Obtained Belarus Drug Registration Certificate

On May 20th, Changshan Pharmaceutical announced that the company had recently received notice that its drug nadroparin calcium injection had obtained a drug registration certificate issued by the Belarusian drug regulatory authority. Na Qu Heparin Calcium Injection is mainly used to treat moderate or high risk situations of venous thrombosis and prevent venous thromboembolic diseases; Treat deep vein thrombosis that has already formed; Combination aspirin is used for the treatment of unstable angina and non-Q-wave myocardial infarction in the acute phase; Prevent blood clot formation during extracorporeal circulation in hemodialysis.

Shanghai Pharmaceutical's rivaroxaban tablets have obtained the approval number from the US FDA

On May 20th, Shanghai Pharmaceuticals announced that its subsidiary Changzhou Pharmaceutical Factory Co., Ltd. has received a notification from the US Food and Drug Administration that its simplified new drug application for rivaroxaban tablets has been approved. Rivaroxaban tablets are mainly used to reduce the risk of stroke and systemic embolism in patients with non valvular atrial fibrillation; Used for the treatment and prevention of deep vein thrombosis (DVT); Used for treating pulmonary embolism (PE); Used to prevent venous thromboembolism (VTE) in patients with acute diseases. In addition, Zhejiang Xinyi Ruijue Pharmaceutical Co., Ltd., a subsidiary of Shanghai Pharmaceutical, received a notice that its brief new drug application for mometasone furoate nasal spray had been approved.

capital market

Kejun Pharmaceutical has completed a B+round financing of over 100 million yuan

On May 20th, Shanghai Kejun Pharmaceutical Technology Co., Ltd. announced the completion of a B+round financing of over 100 million yuan. After completing the joint investment of Guoxin Innovation Equity, Yi'an Group, Infineon Capital, and Honghai Capital in September 2024, this round of financing is funded by Guangdong Science and Technology Corporation's parent fund. The funds raised from this financing will mainly be used to promote the Phase III clinical development of the core product CG-0255 in the field of cardiovascular and cerebrovascular diseases.

Jingyin Pharmaceutical has reached an authorized cooperation on long-acting siRNA new drugs

On May 20th, Jingyin Pharmaceutical and CRISPR Therapeutics announced a strategic partnership to jointly promote the development and commercialization of siRNA therapy. The press release states that this collaboration will combine the complementary capabilities of both parties in research and industrialization to jointly develop and commercialize the next-generation long-acting Factor XI (FXI) targeted small interfering RNA (siRNA) therapy SRSD107 for the treatment of thrombosis and thromboembolic diseases.

Step pharmaceutical holding subsidiary and Fubicheng Pharmaceutical signed a commissioned research and development agreement on MF59 milk adjuvant

On May 20th, Changbu Pharmaceutical announced that its holding subsidiary Zhejiang Tianyuan plans to cooperate with Fubicheng (Shanghai) Pharmaceutical Technology Co., Ltd. on commissioned research and development of MF59 milk adjuvant and sign a commissioned research and development agreement. On the same day, Bu Bu Pharmaceutical announced that in order to vigorously develop and integrate the company's big health industry, the company plans to transfer 1% equity of each of its 9 holding subsidiaries (Ningbo Bu Bu Trading, Shandong Bu Bu Pharmaceutical Cosmetics, Shandong Bu Bu Dingsheng, Shandong Bu Bu Chuanfang, Shandong Bu Bu Youpin, Jinan Bu Bu Chicheng, Jinan Bu Chang Caigan, Jinan Bu Bu Yingxi, and Jinan Bu Bu Zhongfu) to Xie Jihui. Xie Jihui is currently the General Manager of the 17th Division of the company's business.

Industry Events

Sansheng Guojian and Pfizer enter into a licensing agreement for a bispecific antibody product

On May 20, Sansheng Guojian issued an announcement that the company and its related party Sansheng Pharmaceutical and Shenyang Sansheng Pharmaceutical Co., Ltd. jointly granted the licensee Pfizer Inc. the right to exclusively develop, produce and commercialize the licensed product 707 project (i.e., bispecific antibody products targeting PD-1 and VEGF at the same time) in the licensed area (i.e., other countries and regions except Chinese Mainland) and fields (i.e., all treatment, diagnosis and prevention indications for human and veterinary purposes).

Comment 21: Dual antibody drugs, as one of the important tracks for next-generation antibody therapy, are facing increasing technological barriers and clinical value from multinational pharmaceutical companies. Pfizer's move aims to seize the strategic high ground of tumor immunotherapy. While Sansheng Guojian retains the rights and interests of Chinese Mainland, it obtains milestone payments and sales share in overseas markets through license out. This model is also becoming the standard path for domestic leader Biotech.

Public opinion warning

New Yu Jinyu, a shareholder of Jinhua Group, has cumulatively reduced his holdings of 133500 shares in the company

On May 20th, Jinhua Group announced that on May 19th, 2025, the company received a notice from shareholder Xinyu Jinyu stating that from February 18th, 2025 to May 17th, 2025, shareholder Xinyu Jinyu had cumulatively reduced his holdings of 133500 shares (accounting for 0.035765% of the company's total share capital) through centralized bidding. The time period for this reduction plan has expired.

Senior Vice President of Fosun Pharma Resigns Due to Personal Reasons

On May 20th, Fosun Pharma announced that its board of directors has received a written resignation letter from Rong Yang. Due to personal reasons, Rong Yang has applied to resign from his position as Senior Vice President and will no longer hold the position from May 16th, 2025. The board of directors expresses gratitude for his work during his tenure.